Effects of High Intensity Interval Training and Cluster Training on Speed, Explosive Strength and Functional Performance

November 9, 2023 updated by: Riphah International University

Comparative Effects of High Intensity Interval Training and Cluster Training on Speed, Explosive Strength and Functional Performance in Football Players.

High-intensity interval training has been beneficial in many sports and significantly enhanced the results of physical training. Consequently, it has progressively been implemented among the football players. A Cluster Set (CS) is a set that has been broken up into smaller blocks of repeats with the inclusion of brief intra-set breaks or a reorganization of the breaks between repetitions. The initial assumption is that this design would offer a superior rise in exercise quality with the potential to maintain or enhance performance and enable larger loads, leading to stronger performance adaptations. The objective of the study is to compare the effects of high intensity interval training and cluster training on speed, explosive strength and functional performance in football players.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

The objective of the study is to determine the effects of high intensity interval training and cluster training on speed, explosive strength and functional performance in football players.This is randomized clinical trial that will be conducted at football club, Pakistan sport club Lahore. Non-Probability convenient sampling technique will be used to collect data. The study will be completed in 6 months after the approval of ethical committee of RCRS & Allied Health Sciences. Total number of participants will be 54, in group A participants will be 27, in group B participants will be 27. Performance, speed and strength will be measured by using FMS, 30-meter speed test and vertical jump test respectively. The participants will be divided into two groups. Group A will receive high intensity interval training (HIIT) and group B will receive cluster training. The training program will be conducted for 6 weeks and data will be collected pre and post training session. The data will be entered and analyzed using SPSS version 25 and Shapiro wilk test will be applied to determine the normality of the data. If data will be normally distributed then parametric type of statistical test will be applied while if the data will not normally distribute then non parametric type of test will be applied.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
54

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Pakistan
    • Punjab
      • Lahore, Punjab, Pakistan, 52254
        • Recruiting
        • PSB-Coaching Centre, Lahore

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • • Male Players

    • Age between 18-30 years
    • At least 1 years of football experience

Exclusion Criteria:

  • • Individuals with a lower extremity injury

    • Vestibular problems
    • Visual problems
    • Individuals who have had a concussion within the past 6 months

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Tabata Training
HIIT training programs follow Tabata protocol. This protocol was created with the aim of improving the aerobic and anaerobic characteristics beyond the threshold (anaerobic). It consists of performing seven or eight repetitions at maximum intensity, alternating with ten seconds of passive recovery. The series lasts approximately four minutes (240 sec). Given the intensity of the Tabata protocol, it is necessary to finish the workout with a cool down of at least 10-15 minutes. It includes exercises like push-ups, split squats, box jumps, burpees, jumping rope, jumping jacks and more. This training program, lasting about 20 minutes, was repeated three times a week for a total of 6 weeks. The duration of this type of work is not accidental. In fact, it has been scientifically established that only after this period it is possible to find significant improvements in speed, strength and functional activity
Other: Tabata Training
This training program, lasting about 20 minutes, was repeated three times a week for a total of 6 weeks.
Experimental: Cluster Traning
The cluster training consist squat, leg extension, leg curl, heel raise, French curl, barbell curl, Bench press, Incline bench press, behind the neck press with barbell, Overhead press with barbell. The movements were performed in 3 sets, each set containing 9 repetitions with 60-90 seconds of rest between each two sets. Each training session consisted of three steps: Warm up Basic training and Cool-down. Both groups performed the first and the third stage in 10 minutes
Other: Cluster Training
The movements were performed in 3 sets, each set containing 9 repetitions with 60-90 seconds of rest between each two sets.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
FMS (Functional movement screen)
Time Frame: Pre And 6 Weeks Post
The FMS assesses seven fundamental movement patterns that require mobility and stability of the body and limb. These seven movements include the 1) Deep squat (DS) 2) Hurdle step (HS) 3) In-line lunge (IL) 4) Active straight leg raise (ASLR) 5) Trunk push-up (TP) 6) Rotary stability (RS) and 7) Shoulder mobility. Each movement in the FMS is rated by an assessor from 0 to 3 based on their ability to perform the movements without compensatory actions.
Pre And 6 Weeks Post
30 METER SPRINT TEST
Time Frame: Pre And 6 Weeks Post
The purpose of this test is to determine acceleration, maximum running speed and speed endurance, depending on the distance run. The test involves running a single maximum sprint over 30 meters, with the time recorded.
Pre And 6 Weeks Post
THE VERTICAL JUMP TEST
Time Frame: Pre And 6 Weeks Post
A vertical jump test gauge is used to conduct the test. Applicants should stand with their feet level and hip width apart beneath the testing gauge, with their dominant side closer to the gauge. The person then raises their dominant arm and fingers vertically over their head. On the test gauge, the test assessor then set the applicant's reach height to zero (0). The leap must be done with both feet flat on the ground without taking a step or running up from the starting position. To safeguard their lower limbs, candidates must take off and land with both feet. Only two (2) tries are permitted for applicants who must leap 30cm or greater.
Pre And 6 Weeks Post

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Riphah International University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Arslan Sarwar, DPT, study principal investigator

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
August 3, 2023

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
January 3, 2024

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
January 3, 2024

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
November 9, 2023

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 9, 2023

First Posted (Estimated)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
November 14, 2023

Study Record Updates

Last Update Posted (Estimated)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
November 14, 2023

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 9, 2023

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
November 1, 2023

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • REC/RCR & AHS/23/0431

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings